Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Express Scripts
Medtronic
Dow
McKinsey

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

Litigation Details for Bayer Pharma AG v. Watson Laboratories, Inc. (D. Del. 2012)

See Plans and Pricing

« Back to Dashboard

Bayer Pharma AG v. Watson Laboratories, Inc. (D. Del. 2012)

Docket   Start Trial Date Filed 2012-04-25
Court District Court, D. Delaware Date Terminated 2016-05-02
Cause 35:271 Patent Infringement Assigned To Gregory Moneta Sleet
Jury Demand None Referred To
Parties ACTAVIS INC.; ACTAVIS PHARMA INC.; BAYER HEALTHCARE PHARMACEUTICALS INC.; BAYER INTELLECTUAL PROPERTY GMBH; BAYER PHARMA AG; PAR PHARMACEUTICAL COMPANIES INC.; PAR PHARMACEUTICAL INC.; WATSON LABORATORIES INC.; WATSON PHARMA INC.; WATSON PHARMACEUTICALS INC.
Patents 6,362,178; 7,696,206; 8,613,950
Attorneys Brittany A. Merrill; Daniel Brown; David A. Bilson; David Ellis Moore; Emily C. Melvin; Gina R. Gencarelli; J. Anthony Downs; Jack B. Blumenfeld; John C. Phillips , Jr.; John Coy Stull; John W. Bateman; Megan C. Haney; Richard L. Horwitz; Rodger Dallery Smith , II; William G. James; Zaiba Baig
Link to Docket External link to docket
Small Molecule Drugs cited in Bayer Pharma AG v. Watson Laboratories, Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for Bayer Pharma AG v. Watson Laboratories, Inc. (D. Del. 2012)

Date Filed Document No. Description Snippet Link To Document
2012-04-25 1 dysfunction. 24. United States Patent No. 6,362,178 (herein, “the ’178 patent”), entitled “2- Phenyl Substituted…STAXYN® prior to the expiration of U.S. Patent Nos. 6,362,178 and 7,696,206. THE PARTIES 2. Plaintiff…date of the ’178 patent and the ’206 patent. COUNT 1 (Patent Infringement - ’ 178 Patent) 41. Plaintiffs…178 patent and the ’206 patent prior to its filing Paragraph IV Certifications for the ’178 patent and…infringes the ’178 patent or ’206 patent, prior to the expiration date of the ’178 patent or ’206 11 Case External link to document
2015-03-06 130 Pursuant to 35 U.S.C. § 282 Regarding U.S. Patent Nos. 6,362,178, 7,696,206, and 8,613,950 filed by Actavis…April 2012 2 May 2016 1:12-cv-00517-GMS Patent None District Court, D. Delaware External link to document
2015-04-07 139 respect to U.S. Patent Nos. 6,362, 178 ("the '178 patent") and U.S. Patent No. 7,696,2067,696,206 ("the '206 patent"). 2. The Parties agree that the definition …April 2012 2 May 2016 1:12-cv-00517-GMS Patent None District Court, D. Delaware External link to document
2015-06-15 166 of Fact and Conclusions of Law for U.S. Patent No. 8,613,950 by Bayer HealthCare Pharmaceuticals Inc.…April 2012 2 May 2016 1:12-cv-00517-GMS Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Harvard Business School
Baxter
AstraZeneca
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.